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Cohen syndrome is an autosomal recessive condition associated with developmental delay, facial dysmorphism,
pigmentary retinopathy, and neutropenia. The pleiotropic phenotype, combined with insufﬁcient clinical data, often
leads to an erroneous diagnosis and has led to confusion in the literature. Here, we report the results of a com-
prehensive genotype-phenotype study on the largest cohort of patients with Cohen syndrome assembled to date.
We found 22 different COH1 mutations, of which 19 are novel, in probands identiﬁed by our diagnostic criteria.
In addition, we identiﬁed another three novel mutations in patients with incomplete clinical data. By contrast, no
COH1 mutations were found in patients with a provisional diagnosis of Cohen syndrome who did not fulﬁll the
diagnostic criteria (“Cohen-like” syndrome). This study provides a molecular conﬁrmation of the clinical phenotype
associated with Cohen syndrome and provides a basis for laboratory screening that will be valuable in its diagnosis.
Cohen syndrome (COH1 [MIM 216550]) is an auto-
somal recessive condition associated with a complex
phenotype that was described initially in a sib pair and
an unrelated patient with hypotonia, obesity, prominent
incisors, and mental deﬁciency (Cohen et al. 1973). Sub-
sequently, 1100 cases have been reported, 35 of them
from Finland (Kivitie-Kallio and Norio 2001; present
study), where Cohen syndrome is one of several overly
represented autosomal recessive conditions (Norio
2003). The Cohen syndrome phenotype, described in a
cohort of 29 Finnish patients, shows considerable clin-
ical homogeneity, with ﬁve key features identiﬁed: (1)
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nonprogressive mental retardation, motor clumsiness,
and microcephaly; (2) typical facial features; (3) child-
hood hypotonia/joint hyperextensibility; (4) retinocho-
roidal dystrophy and myopia; and (5) isolated neutro-
penia (Kivitie-Kallio and Norio 2001).
Kivitie-Kallio and Norio (2001) reviewed all the re-
ported Cohen syndrome cases worldwide. They con-
cluded that ∼25% (27/110) had features consistent with
those of the Finnish cases. However, the phenotype of
most patients outside of Finland who are claimed to have
Cohen syndrome is highly variable (Kivitie-Kallio and
Norio 2001; Chandler and Clayton-Smith 2002). In-
deed, a second subtype of Cohen syndrome, termed the
“Jewish type” (Kondo et al. 1990), was reported fol-
lowing the description of 39 patients from 32 families
in Israel (Sack and Friedman 1986). Although these pa-
tients had some general features of Cohen syndrome
(e.g., developmental delay, hypotonia, and facial char-
acteristics), they lacked the more speciﬁc features of the
condition (e.g., neutropenia and retinochoroidal dystro-
phy) and also had additional features not associated nor-
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Figure 1 Phenotype of Cohen syndrome. A, Hands showing long tapering ﬁngers. B, Characteristic facial appearance. C, Slender extremities
with truncal obesity. D, Extensive retinal dystrophy with waxy disc pallor and retinal pigmentation.
mally with the disease (e.g., height 197th percentile and
head circumference 197th percentile). Chandler and
Clayton-Smith (2002) concluded that there was insuf-
ﬁcient evidence to support the existence of a “Jewish
type” of Cohen syndrome.
In an attempt to deﬁne the diagnostic criteria for Co-
hen syndrome in patients with a more heterogeneous
genetic background, a study on U.K. patients with Co-
hen syndrome was conducted (Chandler et al. 2002,
2003). Although the above criteria are important di-
agnostic features, they would have identiﬁed only 24%
of the U.K. cohort of patients with “true” Cohen syn-
drome, primarily because of a lack of thorough clinical
investigation. In particular, it is difﬁcult to conﬁrm the
diagnosis of Cohen syndrome in young children (age !5
years), with the use of very strict criteria, when the cho-
rioretinal dystrophy has not yet become manifest or
where there is inadequate information with regard to
ophthalmic examination. These difﬁculties led to the
publication of modiﬁed diagnostic criteria to distinguish
between “true” Cohen and “Cohen-like” syndromes
(Chandler et al. 2002, 2003). In addition to signiﬁcant
learning disabilities, a child with Cohen syndrome had
to have at least two of the following features: facial
gestalt, pigmentary retinopathy, or neutropenia (!2 #
109/mm3) (Chandler et al. 2003) (ﬁg. 1).
Elsewhere, we identiﬁed COH1 as the gene respon-
sible for Cohen syndrome (Kolehmainen et al. 2003).
This novel widely expressed gene is of unknown func-
tion, although homology to the Saccharomyces cerevi-
siae VPS13 protein suggests a role in vesicle-mediated
sorting and intracellular protein trafﬁcking. The iden-
tiﬁcation of the gene now allows a true evaluation of
the clinical criteria for Cohen syndrome, through a mo-
lecular test for the condition.
We have, therefore, undertaken an extensive molec-
ular assessment of a total of 76 patients from 59 families
with a provisional diagnosis of Cohen syndrome and
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have correlated it with clinical ﬁndings. The patients
were assessed for the following eight clinical criteria:
developmental delay, microcephaly, typical Cohen syn-
drome facial gestalt, truncal obesity with slender ex-
tremities, overly sociable behavior, joint hypermobility,
high myopia and/or retinal dystrophy, and neutropenia.
Those fulﬁlling six or more criteria were considered
likely to have true Cohen syndrome. Those with lower
scores (5 of 8) were considered provisionally to have
a Cohen-like syndrome. Ethical approval for this study
was obtained from the relevant authorities in the United
Kingdom and Finland.
Of 37 patients (19 male and 18 female; from 32 fam-
ilies) with Cohen syndrome, 20 met all eight criteria, 12
met seven, and 5 met six. Of the 32 families, 17 were
from the United Kingdom, 9 were from Finland, 2 were
from Belgium, 2 were from Denmark, 1 was of Arab
ethnicity, and 1 was of Dutch extraction. All 37 patients
had developmental delay and the typical facial appear-
ance of Cohen syndrome, and 36 of them had chorio-
retinal dystrophy. Neutropenia was not conﬁrmed in
three patients who all had the typical facial gestalt and
retinal dystrophy.
In the group of 39 patients with a Cohen-like–
syndrome phenotype, full clinical data was available for
22 (from 14 families). Of these 22 patients, 2 met ﬁve
diagnostic criteria, 1 met four, and the remainder met
three or fewer. Speciﬁcally, none of these patients with
Cohen-like syndrome had neutropenia, and only one out
of seven patients with myopia and/or retinal dystrophy
had the typical facial appearance of Cohen syndrome—
and she did not fulﬁll sufﬁciently the other criteria for
a diagnosis of true Cohen syndrome. The clinical data
was incomplete for the remaining 17 patients (from 13
families) with Cohen-like syndrome. Of these patients,
16 fulﬁlled less than six criteria. The patient who did
fulﬁll six criteria lacked both chorioretinal dystrophy
and neutropenia and, therefore, did not meet the criteria
for a diagnosis of true Cohen syndrome (Chandler et al.
2003). Chorioretinal dystrophy was present in four pa-
tients with facial features of Cohen syndrome, and the
retinal status was missing for nine patients. Of those
with a reported leukocyte count (10/17), only one had
neutropenia.
The COH1 gene in 35 of 37 patients with Cohen
syndrome and in 8 patients with Cohen-like syndrome
and incomplete clinical data was screened for sequence
alterations by sequencing 27 overlapping cDNA frag-
ments (Superscript, Invitrogen) with the use of Big Dye
v2.1 (ABI) or by sequencing exon by exon from genomic
DNA with the use of Big Dye v3.1 (ABI) and an ABI
Prism 3730XL DNA Analyzer. Heterozygous frameshift
mutations that could not be pinpointed by this method
were further characterized by TA-cloning (Invitrogen)
followed by sequencing of the insert. The rest of the
patients were screened by SSCP from genomic DNA.
The sequence alterations in COH1 associated with
Cohen syndrome are listed in table 1. We found 22 dif-
ferent sequence alterations (19 of which were novel) in
28 (76%) of 37 patients. Of those patients, 17 had two
sequence alterations (8 homozygous and 9 compound
heterozygous), and 11 had one sequence alteration. The
majority (19/22) of the identiﬁed changes are predicted
to be truncating because of frameshift or nonsense se-
quence alterations. Three different and unknown het-
erozygous sequence alterations are predicted to exist in
separate patients because of the deletion of one or two
whole exons where no sequence alterations were de-
tected in 300 bp of sequence from either side of the
deleted exon(s). The deletion of exon 55 in patient
CV1419 is predicted to be truncating. The deletion of
exon 44 in patient CV1414 and the two-exon deletion
(exons 20 and 21) in an affected sib pair (patients F5
and F6) are predicted to be nontruncating in-frame de-
letions, although it is unknown whether the transcripts
are translated. A third nontruncating sequence alteration
(p.Asn2993Ser) was found as a homozygous change in
a Belgian affected sib pair. In the absence of a functional
assay, it remains possible that this missense change rep-
resents a rare nonpathogenic variant.
Of 19 sequence alterations found by sequencing (ex-
onic deletions not included), 17 were also identiﬁable
by SSCP. None of the identiﬁed sequence alterations
were found in a random panel of at least 192 control
chromosomes (116 chromosomes for nonsense sequence
alterations) screened by SSCP, sequencing, or restriction
digestion of PCR-ampliﬁed genomic DNA. The hetero-
zygous deletion of exons 20 and 21, exon 44, and exon
55 was not screened for in controls; however, for the
latter two deletions, segregation of the mutant allele
from a carrier parent was demonstrated for each of the
probands. For three of the nine patients with Cohen
syndrome in whom no sequence alteration was identi-
ﬁed, there was no evidence of loss of heterozygosity, as
determined with the use of ﬁve STR markers spaced
throughout theCOH1 genomic region (data not shown).
In the group of patients with Cohen-like syndrome
who had incomplete clinical data (17 patients), 1 Israeli
patient (I1) and 1 patient from the United States (US1)
had sequence alterations in COH1 (table 1), increasing
to 25 the total number of COH1 sequence alterations
identiﬁed (22 of which are novel). These additional three
sequence alterations would be expected to result in func-
tional null alleles, either through a frame shift or through
altered splicing. Although both these patients were cat-
egorized initially as having Cohen-like syndrome be-
cause of the lack of full clinical data, patient US1 has
developmental delay, the typical facial gestalt, and cho-
rioretinal dystrophy and fulﬁls the diagnostic criteria for
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Cohen syndrome described by Chandler et al. (2003).
Data for key diagnostic criteria is lacking for the Israeli
patient I1, which makes an unequivocal clinical diag-
nosis of Cohen syndrome impossible. It is highly prob-
able that both patients have Cohen syndrome. It is pos-
sible that some COH1 mutations remain undetected in
the group of patients with incomplete clinical data.
The 22 patients with Cohen-like syndrome and full
clinical data were analyzed by SSCP. This technique
detected 17 (89%) of the 19 mutations described here
for patients with true Cohen syndrome. Only one pa-
tient from this group had a heterozygous change
(p.Ala3753Thr) that was not identiﬁed in 192 CEPH
control chromosomes. This patient lacked the facial ge-
stalt typical of Cohen syndrome, was not neutropenic,
had only mild learning difﬁculties, and had no visual
difﬁculties apart from mild myopia (however, the patient
did not have a full ophthalmological assessment). The
patient is macrocephalic and has truncal obesity and a
sociable personality. This patient does not meet the cri-
teria for true Cohen syndrome. It remains possible that
this sequence alteration is a rare nonpathogenic variant.
We conclude that there is a clear genetic demarcation
between patients with true Cohen syndrome and those
with a Cohen-like syndrome. The demonstration that all
predicted pathogenic COH1 sequence alterations were
found in our patients with Cohen syndrome and that
no such sequence alterations were found in patients with
a Cohen-like syndrome validates our criteria for the ac-
curate diagnosis of this syndrome. These criteria are de-
tailed in Chandler et al. (2003) and include develop-
mental delay, characteristic facial gestalt, chorioretinal
dystrophy, and neutropenia. It should be noted that, as
the neutropenia in Cohen syndrome is intermittent, it
may be undetectable in patients unless repeated differ-
ential counts are made (Norio et al. 1984).
The patients with a Cohen-like syndrome were not
phenotypically homogeneous, which suggests that they
are unlikely to represent a single and separate clinical
grouping. Although SSCP analysis alone cannot exclude
small heterozygous genomic COH1 deletions (in all but
two patients), genetic analyses lend further support for
a demarcation between true Cohen syndrome and
Cohen-like syndromes. Microsatellite analysis using
markers ﬂanking COH1 was undertaken on 12 families
with Cohen-like syndrome. Linkage to the COH1 locus
was excluded in 4 of the 12 families and could be neither
conﬁrmed nor excluded in the remaining 8 families.
The majority (27/31) of COH1 gene alterations
detected in the patients with Cohen syndrome to date
(Kolehmainen et al. 2003; present study) are predicted
to result in a null allele, either through a nonsense change
or through a frameshift resulting in a premature stop
codon. Two mutations (in patients CV1414 and F5/6)
are predicted to cause in-frame deletions. We have de-
scribed two missense alterations: p.Leu2193Arg, re-
ported elsewhere (Kolehmainen et al. 2003), and
p.Asn2993Ser. In the absence of a functional assay,
it remains possible that these missense changes repre-
sent rare nonpathogenic variants. Interestingly, the
p.Asn2993Ser change creates an AG dinucleotide in the
middle of exon 49, immediately upstream of a pyrimi-
dine-rich region, creating the characteristic consensus of
a splice acceptor site. If a new splice site were, indeed,
created by this change, it would predict the deletion of
the ﬁrst 111 bp of exon 49 and an in-frame deletion of
37 aa in the conserved C-terminal VPS13 domain. Sup-
portive evidence for the importance of the VPS13 do-
main can be obtained from the sequencing of RT-PCR
products covering the 3′ end of COH1 (c.9065-12097),
which revealed that in normal lymphoblasts there are
two mRNA forms, the longer of which includes the
entire intron 60. This splice form has also been identi-
ﬁed as a spliced EST (GenBank accession number
BX648610). In this splice form, the ORF for exon 60
is extended by 1 bp into intron 60, before a truncating
stop codon terminates the translation of the full VPS13
domain prematurely. In this study, we have shown that
truncating sequence alterations in exon 62 cause Cohen
syndrome (in patients CV1325 and I1, respectively).
This demonstrates that the full-length splice form (exons
1–62) with the complete C-terminal VPS13 domain is
essential for normal development and, when absent, re-
sults in classical Cohen syndrome.
This study represents the largest screen of patients
with Cohen syndrome and Cohen-like syndrome to date.
It has demonstrated clearly that predicted pathogenic
sequence alterations in COH1 are associated only with
patients with Cohen syndrome, as deﬁned by diagnostic
criteria established elsewhere, and that within this group
there is no apparent genotype-phenotype correlation.
From a clinical perspective, this study has validated the
precise diagnostic criteria necessary for the accurate di-
agnosis of Cohen syndrome and provides a basis for
laboratory screening as part of a diagnostic service. The
importance of the VPS13 domain in development has
been highlighted also, and future work will need to be
directed at elucidating its biological function.
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